Adult Pneumococcal Vaccine Immune Response Studies Could Be Basis For Accelerated Approval, FDA Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Vaccines & Related Biological Products Advisory Committee will consider proposals from Wyeth and GlaxoSmithKline for approval based on antibody titer studies at Nov. 17 meeting.